The Role of the GP in the Management of Ambulatory Heart Failure

NCT05056649 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-06-22

No results posted yet for this study

Summary

To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).

Conditions

Sponsors & Collaborators

  • Jean-Marc BOIVIN

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-09-01
Completion
2023-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05056649 on ClinicalTrials.gov